Antidiabetics Market Size, Share, and Trends 2024 to 2034

The global antidiabetics market size is calculated at USD 116.17 billion in 2025 and is forecasted to reach around USD 244.85 billion by 2034, accelerating at a CAGR of 8.65% from 2025 to 2034. The North America antidiabetics market size surpassed USD 41.66 billion in 2024 and is expanding at a CAGR of 8.79% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.

  • Last Updated : February 2025
  • Report Code : 3914
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Antidiabetics Market 

5.1. COVID-19 Landscape: Antidiabetics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Antidiabetics Market, By Product

8.1. Antidiabetics Market Revenue and Volume, by Product

8.1.1 Insulin

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Drug Class

8.1.2.1. Market Revenue and Volume Forecast

Chapter 9. Global Antidiabetics Market, By Patient Population

9.1. Antidiabetics Market Revenue and Volume, by Patient Population

9.1.1. Pediatric

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Adults

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Geriatric

9.1.3.1. Market Revenue and Volume Forecast

Chapter 10. Global Antidiabetics Market, By Route of Administration 

10.1. Antidiabetics Market Revenue and Volume, by Route of Administration

10.1.1. Oral

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Infusion

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Intravenous

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Insulin Pump

10.1.4.1. Market Revenue and Volume Forecast

10.1.5. Insulin Pen/Syringe

10.1.5.1. Market Revenue and Volume Forecast

Chapter 11. Global Antidiabetics Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Volume Forecast, by Product

11.1.2. Market Revenue and Volume Forecast, by Patient Population

11.1.3. Market Revenue and Volume Forecast, by Route of Administration

11.1.4. U.S.

11.1.4.1. Market Revenue and Volume Forecast, by Product

11.1.4.2. Market Revenue and Volume Forecast, by Patient Population

11.1.4.3. Market Revenue and Volume Forecast, by Route of Administration

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Volume Forecast, by Product

11.1.5.2. Market Revenue and Volume Forecast, by Patient Population

11.1.5.3. Market Revenue and Volume Forecast, by Route of Administration

11.2. Europe

11.2.1. Market Revenue and Volume Forecast, by Product

11.2.2. Market Revenue and Volume Forecast, by Patient Population

11.2.3. Market Revenue and Volume Forecast, by Route of Administration

11.2.4. UK

11.2.4.1. Market Revenue and Volume Forecast, by Product

11.2.4.2. Market Revenue and Volume Forecast, by Patient Population

11.2.4.3. Market Revenue and Volume Forecast, by Route of Administration

11.2.5. Germany

11.2.5.1. Market Revenue and Volume Forecast, by Product

11.2.5.2. Market Revenue and Volume Forecast, by Patient Population

11.2.5.3. Market Revenue and Volume Forecast, by Route of Administration

11.2.6. France

11.2.6.1. Market Revenue and Volume Forecast, by Product

11.2.6.2. Market Revenue and Volume Forecast, by Patient Population

11.2.6.3. Market Revenue and Volume Forecast, by Route of Administration

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Volume Forecast, by Product

11.2.7.2. Market Revenue and Volume Forecast, by Patient Population

11.2.7.3. Market Revenue and Volume Forecast, by Route of Administration

11.3. APAC

11.3.1. Market Revenue and Volume Forecast, by Product

11.3.2. Market Revenue and Volume Forecast, by Patient Population

11.3.3. Market Revenue and Volume Forecast, by Route of Administration

11.3.4. India

11.3.4.1. Market Revenue and Volume Forecast, by Product

11.3.4.2. Market Revenue and Volume Forecast, by Patient Population

11.3.4.3. Market Revenue and Volume Forecast, by Route of Administration

11.3.5. China

11.3.5.1. Market Revenue and Volume Forecast, by Product

11.3.5.2. Market Revenue and Volume Forecast, by Patient Population

11.3.5.3. Market Revenue and Volume Forecast, by Route of Administration

11.3.6. Japan

11.3.6.1. Market Revenue and Volume Forecast, by Product

11.3.6.2. Market Revenue and Volume Forecast, by Patient Population

11.3.6.3. Market Revenue and Volume Forecast, by Route of Administration

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Volume Forecast, by Product

11.3.7.2. Market Revenue and Volume Forecast, by Patient Population

11.3.7.3. Market Revenue and Volume Forecast, by Route of Administration

11.4. MEA

11.4.1. Market Revenue and Volume Forecast, by Product

11.4.2. Market Revenue and Volume Forecast, by Patient Population

11.4.3. Market Revenue and Volume Forecast, by Route of Administration

11.4.4. GCC

11.4.4.1. Market Revenue and Volume Forecast, by Product

11.4.4.2. Market Revenue and Volume Forecast, by Patient Population

11.4.4.3. Market Revenue and Volume Forecast, by Route of Administration

11.4.5. North Africa

11.4.5.1. Market Revenue and Volume Forecast, by Product

11.4.5.2. Market Revenue and Volume Forecast, by Patient Population

11.4.5.3. Market Revenue and Volume Forecast, by Route of Administration

11.4.6. South Africa

11.4.6.1. Market Revenue and Volume Forecast, by Product

11.4.6.2. Market Revenue and Volume Forecast, by Patient Population

11.4.6.3. Market Revenue and Volume Forecast, by Route of Administration

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Volume Forecast, by Product

11.4.7.2. Market Revenue and Volume Forecast, by Patient Population

11.4.7.3. Market Revenue and Volume Forecast, by Route of Administration

11.5. Latin America

11.5.1. Market Revenue and Volume Forecast, by Product

11.5.2. Market Revenue and Volume Forecast, by Patient Population

11.5.3. Market Revenue and Volume Forecast, by Route of Administration

11.5.4. Brazil

11.5.4.1. Market Revenue and Volume Forecast, by Product

11.5.4.2. Market Revenue and Volume Forecast, by Patient Population

11.5.4.3. Market Revenue and Volume Forecast, by Route of Administration

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Volume Forecast, by Product

11.5.5.2. Market Revenue and Volume Forecast, by Patient Population

11.5.5.3. Market Revenue and Volume Forecast, by Route of Administration

Chapter 12. Company Profiles

12.1. Sanofi-Aventis

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Takeda Pharmaceuticals

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Eli Lilly

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Oramed Pharmaceuticals

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Boehringer Ingelheim

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Merck & Co. Inc.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Novo Nordisk

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Bristol-Myers Squibb

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Halozyme Therapeutics

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Pfizer

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global antidiabetics market size is expected to increase USD 244.85 billion by 2034 from USD 106.81 billion in 2024.

The global antidiabetics market will register growth rate of 8.65% between 2025 and 2034.

The major players operating in the antidiabetics market are Sanofi-Aventis, Takeda Pharmaceuticals, Eli Lilly, Oramed Pharmaceuticals, Boehringer Ingelheim, Merck & Co. Inc., Novo Nordisk, Bristol-Myers Squibb, Halozyme Therapeutics, Pfizer, and Others.

The driving factors of the antidiabetics market are the government initiatives for controlling diabetes, rising investments in research and development activities, growing number of diabetes patients.

North America region will lead the global antidiabetics market during the forecast period 2025 to 2034.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client